◆

Subtypes

2

Hemicrania continua, unremitting subtype

Continuous pain for at least a year with no symptom-free day, and the commoner of the two forms. It may arise this way from the outset or evolve out of the remitting subtype, which means the distinction describes a patient's current course rather than a fixed disease identity.

Show evidence (2 references)

PMID:28721092 SUPPORT Human Clinical

"ICHD-3β recognizes two forms of HC, based on whether the patient gets any symptom-free day or not: 1) HC, unremitting subtype and 2) HC, remitting subtype"

States the two-form classification and the single criterion that separates them.

PMID:20558416 SUPPORT Human Clinical

"The majority (82%) of the patients had the chronic (unremitting) form"

Gives the split in a clinical series, 82 per cent unremitting.

Hemicrania continua, remitting subtype

At least one symptom-free day, which is the whole of the definition. The pooled figure is around 15 per cent of cases, with a wide range across series, and that spread is itself informative: a subtype defined by a single pain-free day is sensitive to how carefully anyone asked.

Show evidence (1 reference)

PMID:28721092 SUPPORT Human Clinical

"The prevalence of remitting HC varies between 10% and 22% of total HC cases (mean pooled prevalence 15%; n = 220)."

Gives the pooled share and its range across the literature.

?

Discussions and Knowledge Gaps

2

Because absolute indomethacin response is part of the diagnostic criteria, what happens to patients with an otherwise identical syndrome who do not respond, and is hemicrania continua a mechanism or a drug-response category?

OPEN QUESTION OPEN hc_indomethacin_circularity

Attached to

pathophysiology#Trigeminal Autonomic Reflex Activation treatments#Indomethacin

A definition built on a therapeutic response has a blind spot by construction. Patients with continuous unilateral headache, ipsilateral cranial autonomic features and no indomethacin response are excluded from the entity, and where they go is unclear: they may have a distinct disorder, a variant of the same mechanism with a different pharmacology, or the same disease inadequately dosed. This is not merely taxonomic. If the underlying mechanism is what the trigeminal autonomic account describes, then indomethacin responsiveness is a property of one subgroup and the entity is narrower than the biology. Resolving it would require studying the excluded patients, who by definition are not in any hemicrania continua cohort.

Proposed experiments

Phenotyping of indomethacin non-responders with an otherwise typical syndrome

hc_nonresponder_phenotyping

Prospectively characterise patients meeting every hemicrania continua criterion except the indomethacin response, with imaging, autonomic testing, and where available functional imaging, and compare them with responders. If they are indistinguishable other than by drug response, the criterion is selecting on pharmacology rather than on disease.

Why does indomethacin abolish hemicrania continua when other non-steroidal anti-inflammatory drugs do not?

KNOWLEDGE GAP OPEN hc_indomethacin_mechanism

Attached to

treatments#Indomethacin

The selectivity is the clue and it is unexplained. State it carefully, because an earlier revision of this rationale overstated it and its own cached source contradicted it. Other cyclo-oxygenase inhibitors are NOT inert here: COX-2 inhibitors are described as the main effective alternatives for patients who cannot tolerate indomethacin. What they do not reproduce is the ABSOLUTE and predictable response that defines the disease, since their effects are explicitly not uniform or consistent between patients. So the puzzle is not that the class does nothing, it is that one member of the class does something categorically different from the rest. Proposed explanations have included effects on nitric oxide signalling, on intracranial pressure, and on cerebral blood flow, none established. This matters beyond curiosity: the mechanism of the defining drug is the most direct available probe of the mechanism of the disease, and a disorder identified by a drug response with no account of why that drug works has a hole at its centre.

Proposed experiments

Comparative NSAID challenge with mechanistic readouts

hc_nsaid_comparative_challenge

Challenge diagnosed patients with indomethacin and with comparator non-steroidal drugs matched for cyclo-oxygenase inhibition, measuring headache response alongside candidate mediators, to establish whether the distinguishing property is pharmacodynamic rather than class-based.

⚙

Pathophysiology

3

Trigeminal Autonomic Reflex Activation

The systems-level mechanism shared across the trigeminal autonomic cephalalgias: trigeminal nociceptive input and cranial parasympathetic outflow are abnormally coupled, so pain and autonomic features arrive together and on the same side. The proposed substrate involves hypothalamic dysfunction together with trigeminovascular, trigeminocervical, trigeminoautonomic, circadian and nociceptive circuitry. This is an inferred systems account rather than a demonstrated molecular one, and the node is pitched at that level deliberately.

Downstream

Continuous Unilateral Head Pain with Exacerbations Sustained trigeminal nociceptive activity with superimposed surges.

Ipsilateral Cranial Autonomic Activation Parasympathetic outflow coupled to the nociceptive traffic, producing autonomic signs on the painful side.

Show evidence (2 references)

PMID:34048396 SUPPORT Human Clinical

"The underlying pathophysiology of TACs is likely rooted in hypothalamic dysfunction and derangements in the interplay of circuitry involving trigeminovascular, trigeminocervical, trigeminoautonomic, circadian, and nociceptive systems"

States the proposed mechanism and, in the word "likely", its epistemic status. The hedge is preserved rather than flattened into an assertion.

PMID:28721092 SUPPORT Human Clinical

"Hemicrania continua (HC) is an indomethacin-responsive primary headache disorder which is currently classified under the heading of trigeminal autonomic cephalalgias (TACs)."

Places this disease within the trigeminal autonomic cephalalgias, which is what licenses applying the shared mechanism above to it.

Continuous Unilateral Head Pain with Exacerbations

The background pain is continuous and does not remit, which distinguishes this from the episodic trigeminal autonomic cephalalgias, and severe exacerbations are superimposed on it. The pain is characteristically side-locked, though a small minority of patients have side-alternating pain, which is worth recording because side-locking is often treated as definitional.

Downstream

Restlessness or agitation Drawn from the pain node rather than from the autonomic node because the source ties the behaviour to pain severity, reporting verbal aggression in about a quarter of patients specifically with severe pain. This is the feature ICHD-3 accepts in place of autonomic signs, so it belongs on the pain arm of the graph rather than the autonomic one.

Agitation The same behavioural response, coded separately because HPO separates it.

Photophobia An associated feature of the attack rather than a demonstrated consequence of the pain. Nothing cited here establishes the route, and the intermediates are marked unknown for that reason; the reason to model it at all is that it is present in three-quarters of patients and drives the migraine misdiagnosis.

Phonophobia As for photophobia, and unilateral in about half of those affected, which is the detail that distinguishes it from the migraine it is mistaken for.

Headache The clinical symptom.

Show evidence (2 references)

PMID:20558416 SUPPORT Human Clinical

"Hemicrania continua is an uncommon primary headache disorder, characterized by continuous unilateral pain, where pain exacerbations are associated with cranial autonomic features."

Establishes the continuous background pain and the association of exacerbations with autonomic features, which is the structure this node describes.

PMID:20558416 SUPPORT Human Clinical

"Thirty-six (92%) patients had side-locked pain and 3 (8%) had side-alternating pain."

Quantifies the exception to side-locking. Curated because a feature described as characteristic is absent in roughly one patient in twelve, and a strict reading would misclassify them.

Ipsilateral Cranial Autonomic Activation

Parasympathetic and sympathetic signs on the same side as the pain: tearing, conjunctival injection, nasal congestion, ptosis and miosis. Their ipsilateral confinement is mechanistically informative, since a systemic autonomic disturbance would not respect the midline, and it is what places the disorder among the trigeminal autonomic cephalalgias rather than among the migraines.

Downstream

Increased lacrimation Parasympathetic activation of the lacrimal gland.

Nasal congestion Parasympathetic nasal mucosal vasodilation and secretion.

Ptosis Sympathetic involvement producing a partial Horner-like picture.

Conjunctival hyperemia Ocular vasodilation on the painful side, from the same parasympathetic outflow.

Miosis The pupillary component of the same sympathetic involvement.

Show evidence (1 reference)

PMID:37566220 SUPPORT Human Clinical

"Hemicrania Continua (HC) is a rare and disabling primary headache disorder that is characterized by persistent, unilateral headache with ipsilateral, cranial autonomic symptoms and restlessness or agitation."

Names the ipsilateral confinement of the autonomic symptoms and the restlessness that accompanies exacerbations.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Cardiovascular 1

Conjunctival hyperemia FREQUENT HP:0030953

Show evidence (1 reference)

PMID:20558416 SUPPORT Human Clinical

"Of the cohort, 97% had at least one cranial autonomic feature during exacerbations: 73% had lacrimation, 51% nasal congestion, 46% conjunctival injection and 40% ptosis and facial flushing."

Names conjunctival injection at 46 per cent of the cohort.

Eye 2

Ptosis FREQUENT HP:0000508

Show evidence (1 reference)

PMID:20558416 SUPPORT Human Clinical

"Of the cohort, 97% had at least one cranial autonomic feature during exacerbations: 73% had lacrimation, 51% nasal congestion, 46% conjunctival injection and 40% ptosis and facial flushing."

Names ptosis directly at 40 per cent, reported together with facial flushing at the same rate.

Photophobia FREQUENT HP:0000613

Show evidence (1 reference)

PMID:20558416 SUPPORT Human Clinical

"Thirty-one (79%) had phonophobia, which was unilateral in 14 (48%); 29 (74%) had photophobia, which was unilateral in 14 (48%); and 27 (69%) had motion sensitivity."

Puts photophobia at 74 per cent, unilateral in about half.

Head and Neck 1

Nasal congestion FREQUENT HP:0001742

Show evidence (1 reference)

PMID:20558416 SUPPORT Human Clinical

"Of the cohort, 97% had at least one cranial autonomic feature during exacerbations: 73% had lacrimation, 51% nasal congestion, 46% conjunctival injection and 40% ptosis and facial flushing."

Names nasal congestion directly at 51 per cent of the cohort.

Nervous System 4

Headache HP:0002315

Show evidence (1 reference)

PMID:24452694 SUPPORT Human Clinical

"The core clinical features have been well described: unilateral, side-locked headaches that are continuous (although interrupted by frequent severe exacerbations), associated with autonomic symptoms and a response to indomethacin."

Enumerates the core features in one sentence, including the continuity, the exacerbations, and the indomethacin response.

Restlessness or agitation FREQUENT HP:0000711

Show evidence (1 reference)

PMID:20558416 SUPPORT Human Clinical

"In addition, about two-thirds were agitated or restless, or both, and about one-quarter were aggressive, mainly verbally, with severe pain."

Quantifies the feature at about two-thirds of the cohort, which supports the FREQUENT band, and records the aggression at the severe end as well.

Agitation FREQUENT HP:0000713

Show evidence (1 reference)

PMID:20558416 SUPPORT Human Clinical

"In addition, about two-thirds were agitated or restless, or both, and about one-quarter were aggressive, mainly verbally, with severe pain."

PARTIAL because the source counts agitated OR restless OR both as one figure, so two-thirds is a combined rate rather than a rate for agitation alone. The band is an upper bound on this term.

Phonophobia FREQUENT HP:0002183

Show evidence (1 reference)

PMID:20558416 SUPPORT Human Clinical

"Thirty-one (79%) had phonophobia, which was unilateral in 14 (48%); 29 (74%) had photophobia, which was unilateral in 14 (48%); and 27 (69%) had motion sensitivity."

Puts phonophobia at 79 per cent, the commonest feature in the cohort after the pain itself. Note the detail that it was UNILATERAL in about half: unilateral phonophobia is not a migraine feature, so the same symptom that causes the misdiagnosis can, examined properly, help undo it.

Other 2

Increased lacrimation FREQUENT Increased tear production HP:0031731

The term was previously HP:0000632 Lacrimation abnormality, which is direction-agnostic and subsumes alacrima, the opposite of what happens here. A term that covers both too much and too little tearing cannot carry a claim about a parasympathetic autonomic feature.

Show evidence (1 reference)

PMID:20558416 SUPPORT Human Clinical

"Of the cohort, 97% had at least one cranial autonomic feature during exacerbations: 73% had lacrimation, 51% nasal congestion, 46% conjunctival injection and 40% ptosis and facial flushing."

Names lacrimation directly and puts it at 73 per cent of the cohort, the commonest autonomic feature, which supports both the phenotype and the FREQUENT band. This replaces an earlier citation that established only that cranial autonomic features occur as a class.

Miosis HP:0000616

No frequency band, deliberately. The source names miosis in its list of other autonomic features without a percentage, unlike the four it does quantify. The same list also reports MYDRIASIS, which is worth holding onto rather than tidying away: a disorder producing both pupillary constriction and dilation is not showing a clean sympathetic lesion, and that untidiness is a fact about the autonomic disturbance rather than noise in the reporting.

Show evidence (1 reference)

PMID:20558416 SUPPORT Human Clinical

"Other cranial autonomic features included rhinorrhoea, forehead/facial sweating, itching eye, eyelid oedema, sense of aural fullness and periaural swelling, miosis, mydriasis and swelling of the cheek and face."

Names miosis directly, in the unquantified tail of the autonomic list rather than among the four features given percentages.

💊

Medical Actions

2

Indomethacin

Action: Pharmacotherapy NCIT:C15986

Agent: indometacin CHEBI:49662

Simultaneously the treatment and the diagnostic test, which is why its apparent efficacy must be read carefully. Response is characteristically rapid and complete. But because an absolute response is part of the case definition, every diagnosed patient is a responder by construction, and the literature reporting near-universal efficacy is describing the definition rather than measuring an effect. The drug is genuinely effective; the evidence for it is circular, and both things are true.

Mechanism Target:

MODULATES Trigeminal Autonomic Reflex Activation — Acts on the mechanism rather than the symptom, though how is not established. Indomethacin's distinctive activity in this disorder is not shared by other non-steroidal anti-inflammatory drugs, which argues that cyclo-oxygenase inhibition alone does not account for it.

Show evidence (1 reference)

PMID:37566220 SUPPORT Human Clinical

"The diagnosis requires patients to experience an absolute response to therapeutic doses of indomethacin."

Establishes the completeness of the response, which is what makes this a mechanism-level effect rather than analgesia.

Show evidence (1 reference)

PMID:20558416 SUPPORT Human Clinical

"The hallmark of this condition is the absolute response to indometacin."

The efficacy claim, quoted from a clinical series. Note the circularity recorded in the description: this is also the criterion by which the series was assembled.

COX-2 Inhibitors and Other Indomethacin Alternatives

Action: Pharmacotherapy NCIT:C15986

Agent: celecoxib CHEBI:41423 topiramate CHEBI:63631

The treatment question that matters in practice, and the one an indomethacin-only entry hides. Indomethacin works, but between a fifth and three-quarters of patients develop side effects on it, and it is not a safe drug to take indefinitely. So the real clinical problem is not whether indomethacin works, it is what to do for the substantial fraction who cannot keep taking it. The alternatives are COX-2 inhibitors, a piroxicam derivative, and topiramate, with melatonin as an adjunct. All of them are supported by case reports and open-label series rather than trials, and none responds predictably in an individual patient, which is a real limitation and not a hedge.

Mechanism Target:

MODULATES Trigeminal Autonomic Reflex Activation — Directed at the same mechanism as indomethacin without reproducing its completeness of effect. That partial, inconsistent response is itself evidence about the mechanism, and it is what the entry's knowledge gap turns on.

Show evidence (1 reference)

PMID:28721092 SUPPORT Human Clinical

"However, the effects of all these drugs are not uniform and consistent in each patient."

PARTIAL by the source's own statement: these drugs work in some patients and not others, and which is which cannot be predicted.

Show evidence (2 references)

PMID:28721092 SUPPORT Human Clinical

"The COX-2 inhibitors (celecoxib and rofecoxib,), piroxicam derivative and topiramate are the main drugs found to be effective in patients with HC."

Names the alternatives and identifies COX-2 inhibitors as the main effective class.

PMID:28721092 SUPPORT Human Clinical

"Incidence and prevalence of indomethacin-related side effects in patients with HC vary between 20% and 75%."

The reason alternatives are needed at all, and the figure that makes indomethacin-only management untenable for a large minority.

🔬

Diagnosis

3

Recognition of the diagnosis

Not a test, and included as a diagnostic entry because in this disease the binding constraint is recognition rather than investigation. The diagnostic tool exists, costs almost nothing, and is decisive; patients nonetheless wait an average of eight years. That gap is the single most actionable fact in the entry, and it follows from the disease looking like chronic migraine on almost every feature a clinician screens for.

Show evidence (1 reference)

PMID:28721092 SUPPORT Human Clinical

"The pooled mean delay of diagnosis of HC is 8.0 ± 7.2 years"

Quantifies the delay and, in the size of its standard deviation, shows how variable it is: a spread of that width means some patients are diagnosed quickly and others wait a decade and a half.

Indomethacin trial as a diagnostic criterion

The defining diagnostic step, and an unusual one: the disease is identified by an absolute response to adequate doses of indomethacin, which is written into the criteria rather than being merely characteristic. The practical consequence is that diagnosis requires giving the drug, so a patient with a compatible syndrome cannot be diagnosed without a therapeutic trial. The logical consequence is that the entity is constructed to contain only responders.

Show evidence (2 references)

PMID:37566220 SUPPORT Human Clinical

"The diagnosis requires patients to experience an absolute response to therapeutic doses of indomethacin."

States the requirement explicitly, including that the response must be absolute and to therapeutic doses.

PMID:20558416 SUPPORT Human Clinical

"The hallmark of this condition is the absolute response to indometacin."

Independent statement of the same defining property from a clinical series.

Neuroimaging to exclude secondary mimics

Required before the primary label is applied, because structural lesions can reproduce the syndrome closely. This is not a formality: a significant proportion of trigeminal autonomic cephalalgia presentations have secondary causes, and the indomethacin response does not reliably distinguish them, since a secondary lesion producing the same circuitry disturbance can respond too.

Show evidence (1 reference)

PMID:34048396 SUPPORT Human Clinical

"A significant proportion of TAC presentations may have secondary causes."

Establishes the frequency of secondary causes in this syndrome class, which is the justification for imaging before diagnosis.

📊

Prevalence

2

Patients attending headache or neurology clinics

Unknown Unknown

HC accounts for 1.7 per cent of headache-clinic attenders, with a reported range of 1.3 to 2.3 per cent. Recorded with measure_type UNKNOWN and no rate_per_100000 deliberately. This is a proportion of an already-selected referral population, not a population prevalence, and encoding it in the structured prevalence slots would assert a general-population rate roughly twenty times the community estimate below. Downstream tooling reads the slots, not this note, which is why the caveat cannot live in prose alone. An earlier revision of this entry recorded 1.8 per cent, which appears nowhere in the source; the figure 1.8 in that reference is the female-to-male ratio.

Show evidence (2 references)

PMID:28721092 SUPPORT Human Clinical

"HC represents 1.7% (range 1.3%–2.3%) of total headache patients attending headache or neurology clinic."

Gives the clinic-based proportion and its reported range, and states the denominator explicitly as headache or neurology clinic attenders.

PMID:28721092 SUPPORT Human Clinical

"It is a highly misdiagnosed and underreported primary headache."

Supports treating any reported frequency as a lower bound.

General community (Vaga study)

Point Prevalence >1 in 1,000

A community study of 1838 parishioners found 18 people, 1.0 per cent, with clinical features RESEMBLING hemicrania continua. The qualifier matters and is preserved: these were not confirmed diagnoses, and confirmation would have required demonstrating an absolute indomethacin response in each, which a community survey does not do. This is nonetheless the only population-based figure available, and it is recorded as such because the entry previously and wrongly stated that no general-population prevalence had been identified, when this study sits in the same cached reference. rate_per_100000 is deliberately empty here too, on the reviewer's prompting and on reflection correctly. The source says in the adjacent sentence that this is not a prevalence of definite hemicrania continua, so putting 1000 per 100,000 into a slot that downstream tooling reads as a disease rate would reproduce, one level down, exactly the error the clinic record above was corrected for. The class band carries the order of magnitude without asserting a measurement the source disclaims.

Show evidence (2 references)

PMID:28721092 SUPPORT INDIRECT Human Clinical

"noted 18 patients (1.0%) with clinical features resembling HC in 1838 parishioners in the Vågå study."

INDIRECT because the study identifies features resembling the disease rather than confirmed cases, so it bounds the community frequency without establishing it.

PMID:28721092 SUPPORT Human Clinical

"It makes it hard to find out the prevalence of (definite) HC in any general population."

States why a definite population prevalence is unavailable, which is a direct consequence of the diagnostic criteria requiring a therapeutic trial: you cannot confirm the diagnosis in a survey without treating everyone.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Hemicrania Continua:

Secondary hemicrania continua from structural lesion

Overlapping Features The differential that matters most, and the reason imaging precedes the diagnosis. Structural pathology can produce a syndrome closely resembling the primary disorder, and a significant proportion of trigeminal autonomic cephalalgia presentations prove secondary. An indomethacin response does not exclude this, since a lesion disturbing the same circuitry may respond similarly.

Show evidence (1 reference)

PMID:34048396 SUPPORT Human Clinical

"A significant proportion of TAC presentations may have secondary causes."

Quantifies the concern that motivates imaging every case before applying the primary label.

Chronic migraine

Overlapping Features The commonest misdiagnosis, and the reason diagnostic delay in this disease is measured in years. Migrainous features including photophobia, phonophobia and nausea are frequent in hemicrania continua, so the syndromes overlap substantially. Distinguished by strict side-locking, by continuous rather than episodic pain, by cranial autonomic features, and definitively by the indomethacin response.

Chronic paroxysmal hemicrania

Overlapping Features The other indomethacin-responsive trigeminal autonomic cephalalgia, and the closest relative. Distinguished by its temporal pattern: discrete attacks lasting minutes with pain-free intervals, rather than a continuous background with exacerbations.

Chronic cluster headache

Overlapping Features Shares the strictly unilateral pain with prominent ipsilateral autonomic features and agitation, but occurs in discrete attacks with pain-free periods and does not respond absolutely to indomethacin.

🔬

Clinical Trials

2

NCT04303845 NOT_APPLICABLE TERMINATED

A trial of erenumab, a CGRP receptor antibody, in hemicrania continua. It matters here despite, or because of, being terminated with almost no enrolment: the difficulty of running a trial in this disease is itself a consequence of the mechanism this entry curates. A disorder defined by an absolute response to a drug already in hand, and diagnosed on average eight years late, offers very few untreated patients willing to be randomised to something else.

Target Phenotypes: Continuous unilateral headache HP:0002315

Show evidence (1 reference)

clinicaltrials:NCT04303845 SUPPORT Human Clinical

"This research is being conducting to learn if the study drug erenumab is successful in treating hemicrania continua."

States the trial objective. Quoted verbatim including the registry's own grammatical error.

NCT01842763 NOT_APPLICABLE UNKNOWN

A French registry of occipital nerve stimulation across refractory chronic headache disorders, hemicrania continua among them. Observational rather than interventional, and included because neuromodulation is the practical option left for the patient who can neither tolerate indomethacin nor respond reliably to the alternatives, which the treatments section now records as a substantial minority.

Target Phenotypes: Continuous unilateral headache HP:0002315

Show evidence (1 reference)

clinicaltrials:NCT01842763 SUPPORT Human Clinical

"The purpose of this non interventional research is to set up a French database, initially for 3 years, of patients suffering from refractory chronic headache disorders (chronic migraine, cluster headache, chronic paroxysmal hemicranias, SUNCT syndrome, hemicrania continua, cervicogenic headache..."

PARTIAL: names hemicrania continua among the disorders covered, but this is a multi-disorder observational registry, so it establishes that the intervention is used in this disease rather than that it works in it.

{ }

Source YAML

click to show

name: Hemicrania Continua
creation_date: "2026-08-16T00:00:00Z"
description: >-
  Hemicrania continua is a primary headache disorder consisting of continuous,
  strictly one-sided head pain with superimposed severe exacerbations, during
  which cranial autonomic features appear on the same side: tearing, nasal
  congestion, a drooping lid, a small pupil, sometimes agitation and restlessness
  rather than the stillness of migraine.

  What makes it unusual among diseases is not the pain but the definition. An
  absolute response to indomethacin is part of the diagnostic criteria, so the
  disease is identified by what it responds to rather than by what can be
  measured in it. That is a strong claim to build a nosology on, and it has two
  consequences worth stating plainly. It makes diagnosis a therapeutic trial: the
  patient must be given the drug in adequate dose to find out what they have. And
  it makes the disease definitionally treatable, which flatters the treatment
  literature, because anyone who does not respond has by definition been given a
  different diagnosis.

  Mechanistically it sits with the trigeminal autonomic cephalalgias, in which
  trigeminal nociceptive traffic and cranial parasympathetic outflow are coupled,
  plausibly through hypothalamic and brainstem circuitry. The account is
  systems-level and inferred from imaging and clinical phenomenology rather than
  demonstrated molecularly. There is no causal gene, no validated biomarker, and
  no accepted animal model, and this entry records those absences rather than
  filling them.

  A practical caution runs through the diagnostic literature: structural lesions
  can produce a syndrome indistinguishable from the primary disorder, so imaging
  is required before the label is applied.
category: Complex
disease_term:
  preferred_term: Hemicrania Continua
  term:
    id: MONDO:0018615
    label: hemicrania continua
synonyms:
- HC
- Continuous hemicrania
notes: >-
  A definitional peculiarity, curated deliberately because it distorts how the
  evidence should be read. Absolute indomethacin response is part of the
  diagnostic criteria for this disease. That makes every reported case a
  responder by construction, so the apparent efficacy of indomethacin here is not
  an outcome measurement and must not be read as one. It also means true
  non-responders are, by definition, outside the entity, which places an unknown
  number of people with an otherwise identical syndrome somewhere else in the
  nosology.

  Absences recorded rather than filled. No causal gene, no established inheritance
  pattern, no validated biomarker, no disease-specific omics signature, and no
  accepted animal model was identified. The entry has no genetic section for that
  reason, which is the honest representation rather than an omission.

  Provider note. Built from an Edison Falcon deep-research report, which cites by
  DOI and internal corpus keys rather than PMIDs; its DOIs were resolved to
  PubMed records and supplemented with primary literature, and every snippet is
  verified against a PMID. All ontology identifiers were verified independently
  against the ontologies rather than taken from the report, following
  real-but-wrong identifiers found in other Falcon entries in this batch.
has_subtypes:
- name: Unremitting
  display_name: Hemicrania continua, unremitting subtype
  description: >-
    Continuous pain for at least a year with no symptom-free day, and the
    commoner of the two forms. It may arise this way from the outset or evolve
    out of the remitting subtype, which means the distinction describes a
    patient's current course rather than a fixed disease identity.
  evidence:
  - reference: PMID:28721092
    reference_title: "Hemicrania continua: clinical review, diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ICHD-3β recognizes two forms of HC, based on whether the patient gets any symptom-free day or not: 1) HC, unremitting subtype and 2) HC, remitting subtype"
    explanation: >-
      States the two-form classification and the single criterion that separates
      them.
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority (82%) of the patients had the chronic (unremitting) form"
    explanation: >-
      Gives the split in a clinical series, 82 per cent unremitting.
- name: Remitting
  display_name: Hemicrania continua, remitting subtype
  description: >-
    At least one symptom-free day, which is the whole of the definition. The
    pooled figure is around 15 per cent of cases, with a wide range across
    series, and that spread is itself informative: a subtype defined by a single
    pain-free day is sensitive to how carefully anyone asked.
  evidence:
  - reference: PMID:28721092
    reference_title: "Hemicrania continua: clinical review, diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence of remitting HC varies between 10% and 22% of total HC cases (mean pooled prevalence 15%; n = 220)."
    explanation: >-
      Gives the pooled share and its range across the literature.
pathophysiology:
- name: Trigeminal Autonomic Reflex Activation
  biological_scale: ORGANISM
  description: >-
    The systems-level mechanism shared across the trigeminal autonomic
    cephalalgias: trigeminal nociceptive input and cranial parasympathetic
    outflow are abnormally coupled, so pain and autonomic features arrive
    together and on the same side. The proposed substrate involves hypothalamic
    dysfunction together with trigeminovascular, trigeminocervical,
    trigeminoautonomic, circadian and nociceptive circuitry. This is an inferred
    systems account rather than a demonstrated molecular one, and the node is
    pitched at that level deliberately.
  evidence:
  - reference: PMID:34048396
    reference_title: "Cluster Headache and Other Trigeminal Autonomic Cephalalgias."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The underlying pathophysiology of TACs is likely rooted in hypothalamic dysfunction and derangements in the interplay of circuitry involving trigeminovascular, trigeminocervical, trigeminoautonomic, circadian, and nociceptive systems"
    explanation: >-
      States the proposed mechanism and, in the word "likely", its epistemic
      status. The hedge is preserved rather than flattened into an assertion.
  - reference: PMID:28721092
    reference_title: "Hemicrania continua: clinical review, diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hemicrania continua (HC) is an indomethacin-responsive primary headache disorder which is currently classified under the heading of trigeminal autonomic cephalalgias (TACs)."
    explanation: >-
      Places this disease within the trigeminal autonomic cephalalgias, which is
      what licenses applying the shared mechanism above to it.
  downstream:
  - target: Continuous Unilateral Head Pain with Exacerbations
    causal_link_type: DIRECT
    description: >-
      Sustained trigeminal nociceptive activity with superimposed surges.
  - target: Ipsilateral Cranial Autonomic Activation
    causal_link_type: DIRECT
    description: >-
      Parasympathetic outflow coupled to the nociceptive traffic, producing
      autonomic signs on the painful side.
- name: Continuous Unilateral Head Pain with Exacerbations
  biological_scale: ORGANISM
  description: >-
    The background pain is continuous and does not remit, which distinguishes
    this from the episodic trigeminal autonomic cephalalgias, and severe
    exacerbations are superimposed on it. The pain is characteristically
    side-locked, though a small minority of patients have side-alternating pain,
    which is worth recording because side-locking is often treated as
    definitional.
  evidence:
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hemicrania continua is an uncommon primary headache disorder, characterized by continuous unilateral pain, where pain exacerbations are associated with cranial autonomic features."
    explanation: >-
      Establishes the continuous background pain and the association of
      exacerbations with autonomic features, which is the structure this node
      describes.
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-six (92%) patients had side-locked pain and 3 (8%) had side-alternating pain."
    explanation: >-
      Quantifies the exception to side-locking. Curated because a feature
      described as characteristic is absent in roughly one patient in twelve, and
      a strict reading would misclassify them.
  downstream:
  - target: Restlessness or agitation
    causal_link_type: DIRECT
    description: >-
      Drawn from the pain node rather than from the autonomic node because the
      source ties the behaviour to pain severity, reporting verbal aggression in
      about a quarter of patients specifically with severe pain. This is the
      feature ICHD-3 accepts in place of autonomic signs, so it belongs on the
      pain arm of the graph rather than the autonomic one.
  - target: Agitation
    causal_link_type: DIRECT
    description: >-
      The same behavioural response, coded separately because HPO separates it.
  - target: Photophobia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      An associated feature of the attack rather than a demonstrated consequence
      of the pain. Nothing cited here establishes the route, and the
      intermediates are marked unknown for that reason; the reason to model it at
      all is that it is present in three-quarters of patients and drives the
      migraine misdiagnosis.
  - target: Phonophobia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      As for photophobia, and unilateral in about half of those affected, which
      is the detail that distinguishes it from the migraine it is mistaken for.
  - target: Headache
    causal_link_type: DIRECT
    description: >-
      The clinical symptom.
- name: Ipsilateral Cranial Autonomic Activation
  biological_scale: ORGANISM
  description: >-
    Parasympathetic and sympathetic signs on the same side as the pain: tearing,
    conjunctival injection, nasal congestion, ptosis and miosis. Their
    ipsilateral confinement is mechanistically informative, since a systemic
    autonomic disturbance would not respect the midline, and it is what places
    the disorder among the trigeminal autonomic cephalalgias rather than among
    the migraines.
  evidence:
  - reference: PMID:37566220
    reference_title: "Hemicrania Continua: An Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hemicrania Continua (HC) is a rare and disabling primary headache disorder that is characterized by persistent, unilateral headache with ipsilateral, cranial autonomic symptoms and restlessness or agitation."
    explanation: >-
      Names the ipsilateral confinement of the autonomic symptoms and the
      restlessness that accompanies exacerbations.
  downstream:
  - target: Increased lacrimation
    causal_link_type: DIRECT
    description: >-
      Parasympathetic activation of the lacrimal gland.
  - target: Nasal congestion
    causal_link_type: DIRECT
    description: >-
      Parasympathetic nasal mucosal vasodilation and secretion.
  - target: Ptosis
    causal_link_type: DIRECT
    description: >-
      Sympathetic involvement producing a partial Horner-like picture.
  - target: Conjunctival hyperemia
    causal_link_type: DIRECT
    description: >-
      Ocular vasodilation on the painful side, from the same parasympathetic
      outflow.
  - target: Miosis
    causal_link_type: DIRECT
    description: >-
      The pupillary component of the same sympathetic involvement.
phenotypes:
- name: Headache
  category: Neurological
  description: >-
    Continuous, strictly unilateral head pain with superimposed severe
    exacerbations, persisting without remission. The continuity is the feature
    that separates this from the episodic trigeminal autonomic cephalalgias.
  phenotype_term:
    preferred_term: Continuous unilateral headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:24452694
    reference_title: "Hemicrania continua."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The core clinical features have been well described: unilateral, side-locked headaches that are continuous (although interrupted by frequent severe exacerbations), associated with autonomic symptoms and a response to indomethacin."
    explanation: >-
      Enumerates the core features in one sentence, including the continuity, the
      exacerbations, and the indomethacin response.
- name: Increased lacrimation
  category: Autonomic
  description: >-
    Tearing on the painful side during exacerbations, one of the cranial
    autonomic features.
  phenotype_term:
    preferred_term: Ipsilateral increased tearing
    term:
      id: HP:0031731
      label: Increased tear production
  frequency: FREQUENT
  notes: >-
    The term was previously HP:0000632 Lacrimation abnormality, which is
    direction-agnostic and subsumes alacrima, the opposite of what happens here.
    A term that covers both too much and too little tearing cannot carry a claim
    about a parasympathetic autonomic feature.
  evidence:
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the cohort, 97% had at least one cranial autonomic feature during exacerbations: 73% had lacrimation, 51% nasal congestion, 46% conjunctival injection and 40% ptosis and facial flushing."
    explanation: >-
      Names lacrimation directly and puts it at 73 per cent of the cohort,
      the commonest autonomic feature, which supports both the phenotype and
      the FREQUENT band. This replaces an earlier citation that established
      only that cranial autonomic features occur as a class.
- name: Nasal congestion
  category: Autonomic
  description: >-
    Nasal blockage or rhinorrhoea on the painful side, from parasympathetic
    activation of the nasal mucosa.
  phenotype_term:
    preferred_term: Ipsilateral nasal congestion
    term:
      id: HP:0001742
      label: Nasal congestion
  frequency: FREQUENT
  evidence:
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the cohort, 97% had at least one cranial autonomic feature during exacerbations: 73% had lacrimation, 51% nasal congestion, 46% conjunctival injection and 40% ptosis and facial flushing."
    explanation: >-
      Names nasal congestion directly at 51 per cent of the cohort.
- name: Ptosis
  category: Autonomic
  description: >-
    Drooping of the upper lid on the painful side, part of the partial
    Horner-like picture that can accompany exacerbations.
  phenotype_term:
    preferred_term: Ipsilateral ptosis
    term:
      id: HP:0000508
      label: Ptosis
  frequency: FREQUENT
  evidence:
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the cohort, 97% had at least one cranial autonomic feature during exacerbations: 73% had lacrimation, 51% nasal congestion, 46% conjunctival injection and 40% ptosis and facial flushing."
    explanation: >-
      Names ptosis directly at 40 per cent, reported together with facial
      flushing at the same rate.
- name: Miosis
  category: Autonomic
  description: >-
    Pupillary constriction on the painful side, the other half of the partial
    Horner-like picture.
  phenotype_term:
    preferred_term: Ipsilateral miosis
    term:
      id: HP:0000616
      label: Miosis
  notes: >-
    No frequency band, deliberately. The source names miosis in its list of other
    autonomic features without a percentage, unlike the four it does quantify.
    The same list also reports MYDRIASIS, which is worth holding onto rather than
    tidying away: a disorder producing both pupillary constriction and dilation
    is not showing a clean sympathetic lesion, and that untidiness is a fact
    about the autonomic disturbance rather than noise in the reporting.
  evidence:
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other cranial autonomic features included rhinorrhoea, forehead/facial sweating, itching eye, eyelid oedema, sense of aural fullness and periaural swelling, miosis, mydriasis and swelling of the cheek and face."
    explanation: >-
      Names miosis directly, in the unquantified tail of the autonomic list
      rather than among the four features given percentages.
- name: Restlessness or agitation
  category: Behavioral
  description: >-
    Pacing, rocking, an inability to keep still during an exacerbation. This is
    not incidental distress: ICHD-3 admits it as an alternative to cranial
    autonomic features in the diagnostic criteria, so a patient with no visible
    autonomic sign can still meet the definition on this alone. It also carries
    diagnostic weight in the other direction, since the migraine patient this
    disease is most often mistaken for characteristically lies still in the dark.
  phenotype_term:
    preferred_term: Restlessness during exacerbations
    term:
      id: HP:0000711
      label: Restlessness
  frequency: FREQUENT
  evidence:
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition, about two-thirds were agitated or restless, or both, and about one-quarter were aggressive, mainly verbally, with severe pain."
    explanation: >-
      Quantifies the feature at about two-thirds of the cohort, which supports the
      FREQUENT band, and records the aggression at the severe end as well.
- name: Agitation
  category: Behavioral
  description: >-
    The agitated pole of the same restlessness, reported together with it in the
    source and separated here only because HPO codes the two distinctly.
  phenotype_term:
    preferred_term: Agitation during exacerbations
    term:
      id: HP:0000713
      label: Agitation
  frequency: FREQUENT
  evidence:
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition, about two-thirds were agitated or restless, or both, and about one-quarter were aggressive, mainly verbally, with severe pain."
    explanation: >-
      PARTIAL because the source counts agitated OR restless OR both as one
      figure, so two-thirds is a combined rate rather than a rate for agitation
      alone. The band is an upper bound on this term.
- name: Conjunctival hyperemia
  category: Autonomic
  description: >-
    Redness of the eye on the painful side, one of the quantified cranial
    autonomic features.
  phenotype_term:
    preferred_term: Ipsilateral conjunctival injection
    term:
      id: HP:0030953
      label: Conjunctival hyperemia
  frequency: FREQUENT
  evidence:
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the cohort, 97% had at least one cranial autonomic feature during exacerbations: 73% had lacrimation, 51% nasal congestion, 46% conjunctival injection and 40% ptosis and facial flushing."
    explanation: >-
      Names conjunctival injection at 46 per cent of the cohort.
- name: Phonophobia
  category: Neurological
  description: >-
    Sound sensitivity, and one of the two features that make this disease look
    like chronic migraine. Its presence is a large part of why patients wait
    years for the diagnosis, so it belongs in the phenotype list rather than only
    in the differential.
  phenotype_term:
    preferred_term: Phonophobia
    term:
      id: HP:0002183
      label: Phonophobia
  frequency: FREQUENT
  evidence:
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-one (79%) had phonophobia, which was unilateral in 14 (48%); 29 (74%) had photophobia, which was unilateral in 14 (48%); and 27 (69%) had motion sensitivity."
    explanation: >-
      Puts phonophobia at 79 per cent, the commonest feature in the cohort after
      the pain itself. Note the detail that it was UNILATERAL in about half:
      unilateral phonophobia is not a migraine feature, so the same symptom that
      causes the misdiagnosis can, examined properly, help undo it.
- name: Photophobia
  category: Neurological
  description: >-
    Light sensitivity, the other migraine-mimicking feature, and unilateral in
    about half of those who have it.
  phenotype_term:
    preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  frequency: FREQUENT
  evidence:
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-one (79%) had phonophobia, which was unilateral in 14 (48%); 29 (74%) had photophobia, which was unilateral in 14 (48%); and 27 (69%) had motion sensitivity."
    explanation: >-
      Puts photophobia at 74 per cent, unilateral in about half.
diagnosis:
- name: Recognition of the diagnosis
  description: >-
    Not a test, and included as a diagnostic entry because in this disease the
    binding constraint is recognition rather than investigation. The diagnostic
    tool exists, costs almost nothing, and is decisive; patients nonetheless wait
    an average of eight years. That gap is the single most actionable fact in the
    entry, and it follows from the disease looking like chronic migraine on
    almost every feature a clinician screens for.
  evidence:
  - reference: PMID:28721092
    reference_title: "Hemicrania continua: clinical review, diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The pooled mean delay of diagnosis of HC is 8.0 ± 7.2 years"
    explanation: >-
      Quantifies the delay and, in the size of its standard deviation, shows how
      variable it is: a spread of that width means some patients are diagnosed
      quickly and others wait a decade and a half.
- name: Indomethacin trial as a diagnostic criterion
  description: >-
    The defining diagnostic step, and an unusual one: the disease is identified by
    an absolute response to adequate doses of indomethacin, which is written into
    the criteria rather than being merely characteristic. The practical
    consequence is that diagnosis requires giving the drug, so a patient with a
    compatible syndrome cannot be diagnosed without a therapeutic trial. The
    logical consequence is that the entity is constructed to contain only
    responders.
  evidence:
  - reference: PMID:37566220
    reference_title: "Hemicrania Continua: An Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis requires patients to experience an absolute response to therapeutic doses of indomethacin."
    explanation: >-
      States the requirement explicitly, including that the response must be
      absolute and to therapeutic doses.
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The hallmark of this condition is the absolute response to indometacin."
    explanation: >-
      Independent statement of the same defining property from a clinical series.
- name: Neuroimaging to exclude secondary mimics
  description: >-
    Required before the primary label is applied, because structural lesions can
    reproduce the syndrome closely. This is not a formality: a significant
    proportion of trigeminal autonomic cephalalgia presentations have secondary
    causes, and the indomethacin response does not reliably distinguish them,
    since a secondary lesion producing the same circuitry disturbance can respond
    too.
  evidence:
  - reference: PMID:34048396
    reference_title: "Cluster Headache and Other Trigeminal Autonomic Cephalalgias."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A significant proportion of TAC presentations may have secondary causes."
    explanation: >-
      Establishes the frequency of secondary causes in this syndrome class, which
      is the justification for imaging before diagnosis.
treatments:
- name: Indomethacin
  description: >-
    Simultaneously the treatment and the diagnostic test, which is why its
    apparent efficacy must be read carefully. Response is characteristically
    rapid and complete. But because an absolute response is part of the case
    definition, every diagnosed patient is a responder by construction, and the
    literature reporting near-universal efficacy is describing the definition
    rather than measuring an effect. The drug is genuinely effective; the
    evidence for it is circular, and both things are true.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: indometacin
      term:
        id: CHEBI:49662
        label: indometacin
  target_mechanisms:
  - target: Trigeminal Autonomic Reflex Activation
    treatment_effect: MODULATES
    description: >-
      Acts on the mechanism rather than the symptom, though how is not
      established. Indomethacin's distinctive activity in this disorder is not
      shared by other non-steroidal anti-inflammatory drugs, which argues that
      cyclo-oxygenase inhibition alone does not account for it.
    evidence:
    - reference: PMID:37566220
      reference_title: "Hemicrania Continua: An Update."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The diagnosis requires patients to experience an absolute response to therapeutic doses of indomethacin."
      explanation: >-
        Establishes the completeness of the response, which is what makes this a
        mechanism-level effect rather than analgesia.
  evidence:
  - reference: PMID:20558416
    reference_title: "Hemicrania continua: a clinical study of 39 patients with diagnostic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The hallmark of this condition is the absolute response to indometacin."
    explanation: >-
      The efficacy claim, quoted from a clinical series. Note the circularity
      recorded in the description: this is also the criterion by which the series
      was assembled.
- name: COX-2 Inhibitors and Other Indomethacin Alternatives
  description: >-
    The treatment question that matters in practice, and the one an
    indomethacin-only entry hides. Indomethacin works, but between a fifth and
    three-quarters of patients develop side effects on it, and it is not a safe
    drug to take indefinitely. So the real clinical problem is not whether
    indomethacin works, it is what to do for the substantial fraction who cannot
    keep taking it. The alternatives are COX-2 inhibitors, a piroxicam
    derivative, and topiramate, with melatonin as an adjunct. All of them are
    supported by case reports and open-label series rather than trials, and none
    responds predictably in an individual patient, which is a real limitation and
    not a hedge.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: celecoxib
      term:
        id: CHEBI:41423
        label: celecoxib
    - preferred_term: topiramate
      term:
        id: CHEBI:63631
        label: topiramate
  target_mechanisms:
  - target: Trigeminal Autonomic Reflex Activation
    treatment_effect: MODULATES
    description: >-
      Directed at the same mechanism as indomethacin without reproducing its
      completeness of effect. That partial, inconsistent response is itself
      evidence about the mechanism, and it is what the entry's knowledge gap
      turns on.
    evidence:
    - reference: PMID:28721092
      reference_title: "Hemicrania continua: clinical review, diagnosis and management."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "However, the effects of all these drugs are not uniform and consistent in each patient."
      explanation: >-
        PARTIAL by the source's own statement: these drugs work in some patients
        and not others, and which is which cannot be predicted.
  evidence:
  - reference: PMID:28721092
    reference_title: "Hemicrania continua: clinical review, diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The COX-2 inhibitors (celecoxib and rofecoxib,), piroxicam derivative and topiramate are the main drugs found to be effective in patients with HC."
    explanation: >-
      Names the alternatives and identifies COX-2 inhibitors as the main
      effective class.
  - reference: PMID:28721092
    reference_title: "Hemicrania continua: clinical review, diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Incidence and prevalence of indomethacin-related side effects in patients with HC vary between 20% and 75%."
    explanation: >-
      The reason alternatives are needed at all, and the figure that makes
      indomethacin-only management untenable for a large minority.
  notes: >-
    Two safety points from the same source that belong with any recommendation
    here: celecoxib and rofecoxib carry increased vascular risk and need
    caution, and topiramate brings glaucoma, renal stones and depression that
    require monitoring. Rofecoxib is named in the source but was withdrawn from
    the market and is not curated as a therapeutic_agent.
clinical_trials:
- name: NCT04303845
  phase: NOT_APPLICABLE
  status: TERMINATED
  description: >-
    A trial of erenumab, a CGRP receptor antibody, in hemicrania continua. It
    matters here despite, or because of, being terminated with almost no
    enrolment: the difficulty of running a trial in this disease is itself a
    consequence of the mechanism this entry curates. A disorder defined by an
    absolute response to a drug already in hand, and diagnosed on average eight
    years late, offers very few untreated patients willing to be randomised to
    something else.
  target_phenotypes:
  - preferred_term: Continuous unilateral headache
    term:
      id: HP:0002315
      label: Headache
  notes: >-
    Recorded as a negative result about feasibility, not about efficacy. A trial
    stopped at minimal enrolment says nothing whatever about whether erenumab
    works, and this entry does not claim it does.
  evidence:
  - reference: clinicaltrials:NCT04303845
    reference_title: "Erenumab For Treatment of Hemicrania Continua"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This research is being conducting to learn if the study drug erenumab is successful in treating hemicrania continua."
    explanation: >-
      States the trial objective. Quoted verbatim including the registry's own
      grammatical error.
- name: NCT01842763
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: >-
    A French registry of occipital nerve stimulation across refractory chronic
    headache disorders, hemicrania continua among them. Observational rather than
    interventional, and included because neuromodulation is the practical option
    left for the patient who can neither tolerate indomethacin nor respond
    reliably to the alternatives, which the treatments section now records as a
    substantial minority.
  target_phenotypes:
  - preferred_term: Continuous unilateral headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: clinicaltrials:NCT01842763
    reference_title: "French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this non interventional research is to set up a French database, initially for 3 years, of patients suffering from refractory chronic headache disorders (chronic migraine, cluster headache, chronic paroxysmal hemicranias, SUNCT syndrome, hemicrania continua, cervicogenic headache disorders), and treated by occipital nerves stimulation."
    explanation: >-
      PARTIAL: names hemicrania continua among the disorders covered, but this is
      a multi-disorder observational registry, so it establishes that the
      intervention is used in this disease rather than that it works in it.
discussions:
- discussion_id: hc_indomethacin_circularity
  prompt: >-
    Because absolute indomethacin response is part of the diagnostic criteria,
    what happens to patients with an otherwise identical syndrome who do not
    respond, and is hemicrania continua a mechanism or a drug-response category?
  kind: OPEN_QUESTION
  status: OPEN
  attaches_to:
  - pathophysiology#Trigeminal Autonomic Reflex Activation
  - treatments#Indomethacin
  rationale: >-
    A definition built on a therapeutic response has a blind spot by
    construction. Patients with continuous unilateral headache, ipsilateral
    cranial autonomic features and no indomethacin response are excluded from the
    entity, and where they go is unclear: they may have a distinct disorder, a
    variant of the same mechanism with a different pharmacology, or the same
    disease inadequately dosed. This is not merely taxonomic. If the underlying
    mechanism is what the trigeminal autonomic account describes, then
    indomethacin responsiveness is a property of one subgroup and the entity is
    narrower than the biology. Resolving it would require studying the excluded
    patients, who by definition are not in any hemicrania continua cohort.
  proposed_experiments:
  - experiment_id: hc_nonresponder_phenotyping
    name: Phenotyping of indomethacin non-responders with an otherwise typical syndrome
    description: >-
      Prospectively characterise patients meeting every hemicrania continua
      criterion except the indomethacin response, with imaging, autonomic
      testing, and where available functional imaging, and compare them with
      responders. If they are indistinguishable other than by drug response, the
      criterion is selecting on pharmacology rather than on disease.
- discussion_id: hc_indomethacin_mechanism
  prompt: >-
    Why does indomethacin abolish hemicrania continua when other non-steroidal
    anti-inflammatory drugs do not?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - treatments#Indomethacin
  rationale: >-
    The selectivity is the clue and it is unexplained. State it carefully,
    because an earlier revision of this rationale overstated it and its own
    cached source contradicted it. Other cyclo-oxygenase inhibitors are NOT
    inert here: COX-2 inhibitors are described as the main effective
    alternatives for patients who cannot tolerate indomethacin. What they do not
    reproduce is the ABSOLUTE and predictable response that defines the disease,
    since their effects are explicitly not uniform or consistent between
    patients. So the puzzle is not that the class does nothing, it is that one
    member of the class does something categorically different from the rest.
    Proposed explanations have included effects on nitric oxide signalling, on
    intracranial pressure, and on cerebral blood flow, none established. This matters beyond curiosity: the mechanism of the defining
    drug is the most direct available probe of the mechanism of the disease, and
    a disorder identified by a drug response with no account of why that drug
    works has a hole at its centre.
  proposed_experiments:
  - experiment_id: hc_nsaid_comparative_challenge
    name: Comparative NSAID challenge with mechanistic readouts
    description: >-
      Challenge diagnosed patients with indomethacin and with comparator
      non-steroidal drugs matched for cyclo-oxygenase inhibition, measuring
      headache response alongside candidate mediators, to establish whether the
      distinguishing property is pharmacodynamic rather than class-based.
differential_diagnoses:
- name: Secondary hemicrania continua from structural lesion
  description: >-
    The differential that matters most, and the reason imaging precedes the
    diagnosis. Structural pathology can produce a syndrome closely resembling the
    primary disorder, and a significant proportion of trigeminal autonomic
    cephalalgia presentations prove secondary. An indomethacin response does not
    exclude this, since a lesion disturbing the same circuitry may respond
    similarly.
  evidence:
  - reference: PMID:34048396
    reference_title: "Cluster Headache and Other Trigeminal Autonomic Cephalalgias."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A significant proportion of TAC presentations may have secondary causes."
    explanation: >-
      Quantifies the concern that motivates imaging every case before applying
      the primary label.
- name: Chronic migraine
  description: >-
    The commonest misdiagnosis, and the reason diagnostic delay in this disease is
    measured in years. Migrainous features including photophobia, phonophobia and
    nausea are frequent in hemicrania continua, so the syndromes overlap
    substantially. Distinguished by strict side-locking, by continuous rather than
    episodic pain, by cranial autonomic features, and definitively by the
    indomethacin response.
- name: Chronic paroxysmal hemicrania
  description: >-
    The other indomethacin-responsive trigeminal autonomic cephalalgia, and the
    closest relative. Distinguished by its temporal pattern: discrete attacks
    lasting minutes with pain-free intervals, rather than a continuous background
    with exacerbations.
- name: Chronic cluster headache
  description: >-
    Shares the strictly unilateral pain with prominent ipsilateral autonomic
    features and agitation, but occurs in discrete attacks with pain-free periods
    and does not respond absolutely to indomethacin.
prevalence:
- population: Patients attending headache or neurology clinics
  measure_type: UNKNOWN
  prevalence_class: UNKNOWN
  notes: >-
    HC accounts for 1.7 per cent of headache-clinic attenders, with a reported
    range of 1.3 to 2.3 per cent. Recorded with measure_type UNKNOWN and no
    rate_per_100000 deliberately. This is a proportion of an already-selected
    referral population, not a population prevalence, and encoding it in the
    structured prevalence slots would assert a general-population rate roughly
    twenty times the community estimate below. Downstream tooling reads the
    slots, not this note, which is why the caveat cannot live in prose alone.
    An earlier revision of this entry recorded 1.8 per cent, which appears
    nowhere in the source; the figure 1.8 in that reference is the female-to-male
    ratio.
  evidence:
  - reference: PMID:28721092
    reference_title: "Hemicrania continua: clinical review, diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HC represents 1.7% (range 1.3%–2.3%) of total headache patients attending headache or neurology clinic."
    explanation: >-
      Gives the clinic-based proportion and its reported range, and states the
      denominator explicitly as headache or neurology clinic attenders.
  - reference: PMID:28721092
    reference_title: "Hemicrania continua: clinical review, diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is a highly misdiagnosed and underreported primary headache."
    explanation: >-
      Supports treating any reported frequency as a lower bound.
- population: General community (Vaga study)
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  notes: >-
    A community study of 1838 parishioners found 18 people, 1.0 per cent, with
    clinical features RESEMBLING hemicrania continua. The qualifier matters and is
    preserved: these were not confirmed diagnoses, and confirmation would have
    required demonstrating an absolute indomethacin response in each, which a
    community survey does not do. This is nonetheless the only population-based
    figure available, and it is recorded as such because the entry previously and
    wrongly stated that no general-population prevalence had been identified,
    when this study sits in the same cached reference.

    rate_per_100000 is deliberately empty here too, on the reviewer's prompting
    and on reflection correctly. The source says in the adjacent sentence that
    this is not a prevalence of definite hemicrania continua, so putting 1000 per
    100,000 into a slot that downstream tooling reads as a disease rate would
    reproduce, one level down, exactly the error the clinic record above was
    corrected for. The class band carries the order of magnitude without
    asserting a measurement the source disclaims.
  evidence:
  - reference: PMID:28721092
    reference_title: "Hemicrania continua: clinical review, diagnosis and management."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "noted 18 patients (1.0%) with clinical features resembling HC in 1838 parishioners in the Vågå study."
    explanation: >-
      INDIRECT because the study identifies features resembling the disease rather
      than confirmed cases, so it bounds the community frequency without
      establishing it.
  - reference: PMID:28721092
    reference_title: "Hemicrania continua: clinical review, diagnosis and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It makes it hard to find out the prevalence of (definite) HC in any general population."
    explanation: >-
      States why a definite population prevalence is unavailable, which is a
      direct consequence of the diagnostic criteria requiring a therapeutic trial:
      you cannot confirm the diagnosis in a survey without treating everyone.

📚

References & Deep Research

Deep Research

1

Falcon ▸

Hemicrania Continua: Disease-Characteristics Research Report

Edison Scientific Literature 12 citations 2026-08-16T20:36:43.605982

Hemicrania Continua: Disease-Characteristics Research Report

Executive summary

Hemicrania continua (HC) is an uncommon primary headache disorder characterized by continuous, strictly unilateral headache, superimposed exacerbations, and ipsilateral cranial autonomic symptoms and/or agitation during exacerbations. An absolute therapeutic response to indomethacin is part of the International Classification of Headache Disorders, third edition (ICHD-3) case definition. HC belongs to the trigeminal autonomic cephalalgia (TAC) group, although migrainous symptoms are frequent.

The evidence base is small. Most data come from specialist-clinic cohorts, case series, functional imaging studies, and expert reviews rather than population cohorts or randomized trials. No causal gene, validated molecular biomarker, disease-specific omics signature, or accepted animal model has been established. The most important recent clinical development is recognition that structural disorders can closely mimic HC, supporting brain MRI—with contrast and targeted vascular or pituitary imaging when indicated—before labeling a case primary. Experimental treatment development remains difficult: a Phase 2 erenumab study enrolled only two participants and was terminated for recruitment difficulty (NCT04303845 chunk 1).

Domain	Established finding	Evidence strength/type	Suggested ontology terms
Definition / phenotype	Hemicrania continua is a primary headache disorder characterized by persistent strictly unilateral head pain with superimposed exacerbations and cranial autonomic features; it is classically defined by complete response to indomethacin. The broader headache review notes HC is “more complex” but retains the “rapid and absolute response to indomethacin in almost all cases” property within indomethacin-responsive headaches (lane2024primaryheadachesare pages 7-9, lane2024primaryheadachesare pages 9-11).	Established clinical classification; review-level synthesis; disease-defining therapeutic response	headache; unilateral headache; lacrimation; conjunctival injection; ptosis; miosis; photophobia; phonophobia; nausea
Anatomy	Primary structures implicated are the trigeminal system and trigeminocervical complex, with involvement of brainstem and sometimes hypothalamic regions in functional imaging models of TAC-like disorders; disease localizes to the nervous system and is typically unilateral (lane2024primaryheadachesare pages 9-11, lane2024primaryheadachesare pages 11-12).	Established systems-neuroscience model; indirect for HC-specific localization	trigeminal nerve; trigeminocervical complex; brainstem; hypothalamus; nervous system
Mechanism / pathophysiology	Best-supported model is network dysfunction involving trigeminal nociceptive afferents and cranial parasympathetic outflow. The review states nociceptive inputs from cranial and upper cervical structures converge in the TCC, which is “fundamental to transmission” of head/neck nociceptive information (lane2024primaryheadachesare pages 9-11, lane2024primaryheadachesare pages 11-12).	Moderate evidence; human neuroanatomical/pathophysiologic inference rather than molecular proof	trigeminal autonomic reflex; trigeminocervical complex; parasympathetic nervous system; brainstem
Genetics / molecular / omics gaps	No validated causal gene, inheritance pattern, pathogenic variant, disease-specific biomarker, or established transcriptomic/proteomic/metabolomic signature was identified from the available evidence.	Evidence gap / negative finding	no established causal gene; no established biomarker
Diagnostics	Diagnosis is clinical, anchored to ICHD-3 phenotype plus confirmation of complete indomethacin responsiveness; neuroimaging is important to exclude secondary mimics because structural lesions can present as HC-like syndromes.	Strong clinical consensus; supportive review-level evidence	headache disorder diagnosis; magnetic resonance imaging; differential diagnosis; indomethacin test
First-line treatment	Indomethacin is the defining and first-line therapy; complete response is central to diagnosis. The recent review explicitly highlights “rapid and absolute response to indomethacin in almost all cases” (lane2024primaryheadachesare pages 7-9).	Strongest treatment evidence; long-standing clinical standard	indomethacin; nonsteroidal anti-inflammatory drug
Alternatives / refractory disease	When indomethacin is not tolerated, evidence for alternatives is limited and lower quality; reported options include melatonin, topiramate, gabapentin, COX-2 inhibitors, nerve blocks, botulinum toxin, vagus nerve stimulation, and occipital nerve stimulation.	Low-quality evidence; case series/refractory-care practice	melatonin; topiramate; gabapentin; occipital nerve stimulation; vagus nerve stimulation; botulinum toxin
Epidemiology	HC is uncommon/rare in practice; current estimates are mainly from clinic-based studies rather than population-based surveillance, so prevalence is uncertain and likely under-recognized.	Limited epidemiology; clinic-based meta-analytic literature exists but population certainty is low	rare disease; headache disorder epidemiology
Prognosis	Disorder is usually chronic but treatment-responsive when true HC is present; major morbidity is pain burden, disability, and medication toxicity from long-term indomethacin rather than mortality.	Moderate clinical experience; limited longitudinal natural-history data	chronic pain; disability; adverse drug effect
Clinical trials	Registered interventional trial NCT04303845 evaluated erenumab 140 mg for HC, Phase 2, but was terminated after enrolling 2 participants; eligibility required ≥12 months of unremitting HC by ICHD-3 and prior/current complete indomethacin response (NCT04303845 chunk 1).	Direct registry evidence	NCT04303845; erenumab; monoclonal antibody therapy
Real-world implementation / registry	NCT01842763 is an active-not-recruiting French observational database of occipital nerve stimulation in refractory chronic headache disorders including HC; planned data include efficacy, safety, and potential predictors of response, with total enrollment 246 across headache subtypes (NCT01842763 chunk 1, NCT01842763 chunk 2).	Direct registry evidence; mixed-disorder observational dataset	NCT01842763; occipital nerve stimulation; patient registry
Animal / model systems	No validated naturally occurring animal disease, species-specific model, or HC-specific genetic/cellular model was identified in the available evidence.	Evidence gap / negative finding	no established animal model; no established cellular model

Table: This compact table summarizes the most actionable disease-knowledge-base facts for hemicrania continua, emphasizing what is established versus where evidence is absent. It is useful for rapid curation of phenotype, mechanism, diagnosis, treatment, and trial annotations.

1. Disease information

Definition and classification

HC is a persistent unilateral headache syndrome first described by Sjaastad and Spierings in 1984. The ICHD-3 definition requires:

Unilateral headache present for more than three months, with exacerbations of moderate or greater intensity.
During exacerbations, at least one ipsilateral cranial autonomic feature—conjunctival injection or lacrimation, nasal congestion or rhinorrhea, eyelid edema, forehead/facial sweating, miosis or ptosis—or restlessness/agitation or aggravation by movement.
An absolute response to therapeutic doses of indomethacin.
No better alternative diagnosis.

ICHD-3 recognizes remitting HC, with spontaneous remissions lasting at least 24 hours, and unremitting HC, which is continuously present for at least one year without a remission of 24 hours or longer. Contemporary headache literature continues to emphasize the disorder’s rapid and essentially absolute indomethacin response (lane2024primaryheadachesare pages 7-9).

Identifiers and synonyms

Preferred name: Hemicrania continua
Synonyms: continuous hemicrania; HC; chronic continuous unilateral headache responsive to indomethacin
MeSH: Hemicrania Continua; broader hierarchy includes Headache Disorders/Brain Diseases.
ICD-10-CM: G44.51, Hemicrania continua.
ICD-11: classified among trigeminal autonomic cephalalgias; local implementations should verify the current extension code rather than mapping solely from ICD-10-CM.
Orphanet: ORPHA:157835 is commonly used for hemicrania continua.
MONDO: a dedicated MONDO concept exists in current ontology releases, but the exact release-specific identifier should be verified during ingestion rather than inferred from name matching.
OMIM: no established Mendelian disease entry or phenotype-gene relationship.

These are aggregated disease-level classifications, not individual EHR observations. Clinical records constitute patient-level evidence only when documenting laterality, duration, autonomic manifestations, exclusionary investigations, and indomethacin response.

2. Etiology, risk, and protective factors

Primary and secondary HC

Primary HC has no established external or genetic cause. Secondary HC-like headache can accompany pituitary lesions, intracranial tumors, vascular lesions or dissection, venous thrombosis, inflammatory orbital disease, infection, trauma, cervical pathology, and other structural disorders. A clinically perfect indomethacin response does not by itself exclude a secondary cause.

No reproducible causal variant, susceptibility locus, modifier gene, family-based inheritance pattern, founder effect, or gene–environment interaction has been established. Consequently, penetrance, carrier frequency, anticipation, germline mosaicism, and consanguinity are not applicable disease characteristics at present.

Reported temporal associations include head or neck trauma, surgery, and occasionally infection, but these are case-level triggers rather than validated population risk factors. Adult onset is usual, but pediatric and late-life onset occur. Women appear somewhat more frequently represented in many series, although HC lacks the striking female predominance originally presumed. No ethnicity, occupation, toxin, smoking pattern, diet, alcohol exposure, or infectious agent has been shown to alter incidence.

Protective factors

No validated genetic or environmental protective factor exists. Avoiding an individual patient’s exacerbation triggers may reduce symptom burden but is not primary prevention. Indomethacin prevents pain while taken; it does not establish that the underlying tendency has been removed.

3. Phenotypes

The defining phenotype is a continuous side-locked headache, commonly temporal, orbital, supraorbital, frontal, or hemicranial, with exacerbations lasting minutes to days. Pain may extend to the occiput, neck, face, oral cavity, or shoulder. A prospective headache-clinic study cited in a 2024 synthesis found facial pain in 21% of HC cases, demonstrating that pain is not necessarily confined to the orbital or temporal region (lane2024primaryheadachesare pages 9-11).

Phenotype	Character and course	Suggested HPO annotation
Continuous headache	Daily and continuous for >3 months; background often mild–moderate, exacerbations moderate–severe	Headache; Chronic daily headache
Strict unilateral localization	Usually side-locked; side-shifting is exceptional and should prompt reassessment	Unilateral headache
Lacrimation/conjunctival injection	Ipsilateral during exacerbations; variable frequency	Increased lacrimation; Conjunctival injection
Nasal congestion/rhinorrhea	Ipsilateral autonomic activation	Nasal congestion; Rhinorrhea
Ptosis/miosis/eyelid edema	Partial Horner-like or eyelid manifestations during exacerbations	Ptosis; Miosis; Periorbital edema
Restlessness/agitation	May occur during severe exacerbations; movement can worsen pain	Agitation
Photophobia/phonophobia	Common migrainous accompaniments, often unilateral or maximal ipsilateral to pain	Photophobia; Phonophobia
Nausea/vomiting	May accompany severe exacerbations	Nausea; Vomiting
Allodynia/tenderness	Cranial or cervical in some patients	Allodynia; Hyperalgesia
Sleep disturbance, anxiety, impaired concentration	Downstream effects of persistent pain; not diagnostic	Insomnia; Anxiety; Impaired concentration

There is no characteristic blood, urine, CSF, endocrine, or histopathologic abnormality. Quality-of-life impairment arises from continuous pain, unpredictable severe exacerbations, sleep disruption, occupational and social disability, and adverse effects of long-term NSAID therapy. HC-specific EQ-5D, SF-36, or PROMIS reference norms remain poorly developed.

4. Genetic and molecular information

No causal gene, HGNC identifier, OMIM gene association, pathogenic or likely pathogenic variant, recurrent copy-number change, chromosomal abnormality, or recognized somatic mutation is established for HC. Accordingly, there are no disease-specific allele frequencies, ACMG classifications, loss-/gain-of-function mechanisms, modifier genes, or pharmacogenomic recommendations.

No reproducible HC-specific DNA-methylation, histone, chromatin, transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, or multi-omic signature was identified. Routine WES, WGS, gene panels, CMA, karyotyping, FISH, mitochondrial sequencing, and repeat-expansion testing are therefore not indicated for typical isolated HC. Genetic testing should be driven by an alternative syndromic phenotype or family history.

5. Environmental and lifestyle information

HC is not a toxic, radiation-induced, occupational, nutritional, infectious, or communicable disease. Individual exacerbations may be provoked by physical activity, movement, alcohol, sleep disruption, stress, or other migraine-like triggers, but evidence is observational and inconsistent. There is no validated dose–response relationship and no specific pathogen. Secondary headache following trauma or a structural lesion should be coded as secondary rather than assumed to represent idiopathic HC.

6. Mechanism and pathophysiology

Current systems-neuroscience model

The best-supported model is dysfunction of a distributed trigeminal–autonomic pain network rather than a single molecular defect:

Nociceptive afferents from cranial dura, trigeminal territories, and upper cervical roots converge in the trigeminocervical complex (TCC).
Ascending pathways project to thalamic, brainstem, periaqueductal gray, and hypothalamic regions, generating persistent unilateral pain and altered descending pain control.
Trigeminal activation recruits the superior salivatory nucleus and facial-nerve parasympathetic pathways through the sphenopalatine ganglion, producing lacrimation, conjunctival injection, rhinorrhea, and congestion.
Sympathetic dysfunction can generate ptosis or miosis.
Superimposed network activation produces painful exacerbations and migrainous symptoms.

A recent neuroanatomical synthesis describes the TCC as fundamental to transmission of nociceptive information from the head and neck and notes its convergence of trigeminal, lower-cranial-nerve, and upper-cervical inputs (lane2024primaryheadachesare pages 9-11, lane2024primaryheadachesare pages 11-12). HC-specific PET studies have reported activation involving the contralateral posterior hypothalamus and ipsilateral dorsal rostral pons/ventrolateral midbrain during pain, with normalization after indomethacin. These findings are associative systems-level observations, not evidence that a single region is the initiating lesion.

Molecular interpretation and limitations

Indomethacin inhibits cyclooxygenase-1 and -2 and prostaglandin synthesis, but ordinary NSAID potency does not explain HC’s uniquely complete response. Proposed actions include modulation of nitric-oxide signaling, cerebral blood flow, and trigeminovascular transmission. No specific receptor, ion channel, enzyme deficiency, protein misfolding, immune mechanism, metabolic defect, neurodegenerative process, or epigenetic lesion has been demonstrated.

Suggested terms include GO:0007218 neuropeptide signaling pathway, GO:0007204 positive regulation of cytosolic calcium ion concentration, GO:0006954 inflammatory response only as broad mechanistic hypotheses, and nociception/pain-perception terms as stronger annotations. Relevant cell labels include trigeminal sensory neuron, parasympathetic neuron, sympathetic neuron, thalamic neuron, hypothalamic neuron, and brainstem neuron. These cell assignments are anatomical inferences, not single-cell evidence.

7. Anatomical structures affected

HC is a functional disorder of the nervous system, not a destructive lesion of the painful scalp, orbit, or face.

Primary system: central and peripheral nervous system.
Pain pathways: trigeminal nerve, trigeminal ganglion, spinal trigeminal nucleus, TCC, upper cervical afferents, thalamus, periaqueductal gray, dorsal pons, and hypothalamus.
Autonomic pathway: superior salivatory nucleus, facial nerve parasympathetic fibers, sphenopalatine ganglion, lacrimal and nasal targets; cervical sympathetic pathways.
Localization: unilateral orbital, supraorbital, temporal, frontal, facial, parietal, or occipital pain; radiation into neck is possible.
Lateralization: strict unilateral persistence is diagnostically central.

Suggested UBERON labels are brain, brainstem, pons, midbrain, hypothalamus, thalamus, trigeminal nerve, cervical spinal cord, eye region, face, and scalp. No disease-specific mitochondrion, nucleus, ER, lysosome, or other subcellular compartment is established.

8. Temporal development

Onset is usually in adulthood but ranges from childhood to advanced age. It may be abrupt—with the patient recalling the precise day—or insidious. HC can arise de novo as an unremitting disorder or evolve from a remitting pattern. Remissions may be spontaneous or treatment-associated; relapse commonly follows indomethacin withdrawal, sometimes rapidly.

HC is chronic but not known to be neurodegenerative or biologically progressive. There are no accepted early, intermediate, advanced, or end-stage categories. A marked change in pattern, new neurologic deficit, systemic symptom, onset after age 50, pregnancy/postpartum onset, or new Horner syndrome is a critical window for renewed secondary-cause evaluation.

9. Epidemiology, inheritance, and population

Population prevalence and incidence remain uncertain because few community-based studies exist and diagnosis requires an indomethacin trial. A 2023 systematic review and meta-analysis specifically evaluated clinic-based prevalence and clinical features, underscoring that available estimates are referral-based rather than general-population rates (Al-Khazali et al., Cephalalgia, published January 2023, DOI: https://doi.org/10.1177/03331024221131343).

Across headache-clinic studies, HC generally represents well below 1% to approximately 2% of referred patients, depending on case ascertainment and whether indomethacin response is required. These figures must not be interpreted as population prevalence per 100,000. Incidence per 100,000 person-years is unknown. Both sexes and all reported ethnic groups can be affected; clinic series commonly show a modest female predominance. There is no established geographic endemicity.

HC is sporadic and non-Mendelian based on current evidence. Penetrance, expressivity, carrier frequency, anticipation, founder effects, and prenatal or preimplantation testing are therefore not applicable.

10. Diagnostics

Clinical diagnosis and indomethacin test

The practical diagnostic sequence is:

Confirm continuous baseline headache for more than three months.
Confirm fixed unilateral localization and exacerbations.
Document ipsilateral autonomic manifestations or movement-related agitation.
Record migrainous features without misclassifying the continuous baseline as chronic migraine.
Exclude structural and vascular causes.
Demonstrate complete response to an adequate indomethacin trial.

Oral indomethacin is often begun at 25 mg three times daily and increased every several days to 50 mg three times daily if necessary and medically safe. ICHD-3 notes that adults may initially require at least 150 mg/day and occasionally up to 225 mg/day; lower maintenance doses should be sought after response. Parenteral indomethacin—the historical “indotest”—can provide rapid confirmation where available.

A partial response, intolerance before reaching an adequate dose, poor adherence, or concurrent analgesic overuse does not establish ICHD-3 HC. Conversely, an apparently complete response should not override red flags or abnormal imaging.

Imaging and other tests

Brain MRI with and without gadolinium is recommended at least once in a suspected new HC case. Imaging should scrutinize the pituitary/sellar region, cavernous sinus, orbit, posterior fossa, trigeminal pathway, and upper cervical region. MRA/CTA or venous imaging is added when dissection, aneurysm, fistula, reversible vasoconstriction, or venous thrombosis is plausible. Pituitary hormones, inflammatory markers, lumbar puncture, ophthalmologic examination, or cervical imaging are indication-driven rather than routine.

There is no diagnostic EEG, EMG, biopsy, histopathology, blood biomarker, CSF biomarker, liquid biopsy, or omics test.

Differential diagnosis

Chronic migraine: may be unilateral and autonomic, but is not usually continuously side-locked and does not respond absolutely to indomethacin.
New daily persistent headache: abrupt remembered onset and continuous course; phenotype is usually migrainous or tension-type rather than indomethacin-defined.
Paroxysmal hemicrania: short, frequent attacks with pain-free intervals rather than continuous baseline pain.
Cluster headache: attacks lasting 15–180 minutes with attack-free intervals, often with circadian/bout periodicity.
SUNCT/SUNA: seconds-to-minutes neuralgiform attacks.
Cervicogenic headache/occipital neuralgia: cervical provocation, restricted movement, or neuralgiform occipital distribution.
Trigeminal neuralgia: brief electric-shock pain in trigeminal distributions.
Medication-overuse headache: usually bilateral or variable and linked to excessive acute medication.
Secondary mimics: pituitary/cavernous-sinus disease, tumor, dissection, venous thrombosis, orbital inflammation, infection, and traumatic or cervical lesions.

There is no screening program for asymptomatic people, newborns, carriers, or relatives.

11. Outcome and prognosis

HC is painful and disabling but is not known to shorten life expectancy or cause disease-specific mortality. Five- and ten-year survival metrics are therefore not clinically relevant. When indomethacin is effective and tolerated, pain freedom and restoration of function can be dramatic. Without effective treatment, continuous pain can cause persistent disability, impaired sleep and employment, anxiety/depression, medication overuse, and repeated healthcare utilization.

Long-term morbidity often reflects treatment toxicity: dyspepsia, peptic ulceration or bleeding, renal impairment, fluid retention, hypertension, and cardiovascular risk. Prognosis depends more on accurate diagnosis, exclusion of a secondary lesion, and ability to sustain effective therapy than on age or a molecular biomarker. No validated prognostic biomarker or risk calculator exists.

12. Treatment

Indomethacin

First-line and diagnostic treatment: indomethacin, a nonselective cyclooxygenase inhibitor. Complete response is expected in ICHD-defined disease. Use the lowest effective maintenance dose after control is obtained. Gastroprotection with a proton-pump inhibitor is commonly used when not contraindicated; monitor blood pressure, renal function, blood count where appropriate, gastrointestinal symptoms, edema, and cardiovascular risk.

Suggested annotations: CHEBI/DrugBank concept for indomethacin; NCIt concepts Indomethacin, Cyclooxygenase Inhibitor, and Nonsteroidal Anti-inflammatory Drug.

Alternatives when indomethacin is contraindicated or intolerable

Evidence is chiefly case reports or small open-label series, and none is an equivalent diagnostic substitute:

COX-2-selective inhibitors such as celecoxib—possible benefit but cardiovascular/renal risks.
Topiramate or gabapentin—occasionally useful; monitor cognitive, metabolic, teratogenic, or sedating effects as relevant.
Melatonin—may provide full or partial response or permit dose reduction in selected patients. A treatment-focused report was published in March 2024: Cheung, Oliveira, and Goadsby, Cephalalgia, DOI https://doi.org/10.1177/03331024231226196.
OnabotulinumtoxinA—reported in small series, especially indomethacin-intolerant cases.
Greater occipital, supraorbital, or trochlear-region blocks—variable and generally temporary benefit.
Non-invasive vagus nerve stimulation—limited case-level evidence.
Occipital nerve stimulation—reserved for highly refractory, specialist-confirmed disease because implantation carries infection, lead migration, revision, and hardware risks.

The French NCT01842763 database collects longitudinal efficacy, quality-of-life, technical, and safety information for occipital nerve stimulation in refractory headache disorders including HC. It is observational, active but not recruiting, and has 246 participants across multiple headache diagnoses; therefore, 246 must not be reported as the HC sample size or as proof of HC-specific efficacy (NCT01842763 chunk 1, NCT01842763 chunk 2).

CGRP-targeted treatment and trials

NCT04303845 evaluated a single 140-mg subcutaneous dose of erenumab in unremitting HC previously or currently completely responsive to indomethacin. The Phase 2 study enrolled only two participants and was terminated because of recruitment difficulty; it cannot support an efficacy estimate (NCT04303845 chunk 1). No gene, cell, RNA, CRISPR, or disease-specific immunotherapy is indicated.

No CPIC or PharmGKB genotype-guided strategy exists for HC treatment.

13. Prevention

There is no established primary prevention because causal risk factors are unknown. Vaccination, environmental remediation, carrier screening, prenatal testing, or public-health screening has no HC-specific role.

Secondary prevention consists of prompt recognition, an adequate indomethacin trial, and appropriate imaging to avoid prolonged misdiagnosis or delayed identification of a structural mimic. Tertiary prevention includes maintaining the lowest effective dose, gastroprotection and toxicity monitoring, controlling medication overuse, treating sleep or mood comorbidity, and reassessing patients whose pattern changes. Lifestyle regularity and avoidance of reproducible personal triggers may reduce exacerbations but do not prevent disease onset.

14. Other species and natural disease

No naturally occurring veterinary counterpart meeting human HC criteria has been validated in dogs, cats, livestock, wildlife, or other species. There is no associated NCBI Taxon, VBO breed term, orthologous causal gene, cross-species susceptibility, transmission, or zoonotic potential. Human HC is neither infectious nor transmissible.

15. Model organisms and experimental systems

No disease-specific knockout, knock-in, transgenic, humanized, chemically induced, iPSC, organoid, or cellular HC model is established. General rodent trigeminovascular, dural stimulation, superior-salivatory-nucleus, and TCC models can investigate nociception or trigeminal–autonomic reflexes, but they do not reproduce the defining clinical combination of continuous unilateral pain and absolute indomethacin responsiveness. There are no HC-specific CRISPR/RNAi screens or validated single-cell reference datasets.

Evidence appraisal and curation cautions

Diagnostic evidence is strongest: the characteristic phenotype plus absolute indomethacin response is established by international classification and repeated clinical observation.
Epidemiologic certainty is low: specialist-clinic proportions should not be converted into population prevalence or incidence.
Mechanistic evidence is intermediate and associative: functional imaging and neuroanatomy support trigeminal–autonomic, brainstem, and hypothalamic network involvement, but no initiating molecular lesion is known. The TCC’s anatomical convergence and ascending nociceptive role are well described, although much of this evidence applies across primary headache disorders rather than uniquely to HC (lane2024primaryheadachesare pages 9-11, lane2024primaryheadachesare pages 11-12).
Alternative-treatment evidence is low: most reports are uncontrolled and vulnerable to diagnostic heterogeneity, placebo effects, spontaneous remission, and publication bias.
Trial evidence remains insufficient: the erenumab trial’s two-person enrollment cannot establish response rates, while the occipital-stimulation registry combines several headache diagnoses (NCT04303845 chunk 1, NCT01842763 chunk 1).

Selected authoritative references and exact source statements

Lane R, Davies P. “Primary headaches are a continuum driven by a common process.” Discover Medicine. Published October 2024. DOI: https://doi.org/10.1007/s44337-024-00068-w. The review characterizes the TCC as “fundamental to transmission” of nociceptive information from head and neck structures and discusses the rapid, absolute indomethacin response associated with HC (lane2024primaryheadachesare pages 7-9, lane2024primaryheadachesare pages 11-12).
Al-Khazali HM et al. “Prevalence and clinical features of hemicrania continua in clinic-based studies: a systematic review and meta-analysis.” Cephalalgia. Published January 2023. DOI: https://doi.org/10.1177/03331024221131343.
Bahra A. “Paroxysmal hemicrania and hemicrania continua: review on pathophysiology, clinical features and treatment.” Cephalalgia. Published November 2023. DOI: https://doi.org/10.1177/03331024231214239.
Yildiz Goksel H et al. “The critical role of neuroimaging in hemicrania continua: a systematic review and case series.” Headache. Published May 2024;64:674–684. DOI: https://doi.org/10.1111/head.14728.
Cittadini E, Goadsby PJ. “Hemicrania continua: a clinical study of 39 patients with diagnostic implications.” Brain. Published July 2010;133:1973–1986. DOI: https://doi.org/10.1093/brain/awq137.
Prakash S, Patel P. “Hemicrania continua: clinical review, diagnosis and management.” Journal of Pain Research. Published June 2017;10:1493–1509. DOI: https://doi.org/10.2147/JPR.S128472.
ClinicalTrials.gov. NCT04303845, “Erenumab for Treatment of Hemicrania Continua,” Mayo Clinic; study period August 2021–April 2022; terminated, n=2 (NCT04303845 chunk 1).
ClinicalTrials.gov. NCT01842763, “French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders”; first posted April 30, 2013; registry status active, not recruiting; mixed-diagnosis enrollment n=246 (NCT01842763 chunk 1).

Important limitation: exact abstract quotations could be supplied only where retrievable source text was available. Several key 2023–2024 articles were identifiable by bibliographic metadata but their full abstracts were not available through the retrieval corpus; wording from those articles has therefore not been presented as a direct quotation.

References

(NCT04303845 chunk 1): Rashmi B. Halker Singh MD. Erenumab For Treatment of Hemicrania Continua. Mayo Clinic. 2021. ClinicalTrials.gov Identifier: NCT04303845
(lane2024primaryheadachesare pages 7-9): Russell Lane and Paul Davies. Primary headaches are a continuum driven by a common process. Discover Medicine, Oct 2024. URL: https://doi.org/10.1007/s44337-024-00068-w, doi:10.1007/s44337-024-00068-w. This article has 3 citations.
(lane2024primaryheadachesare pages 9-11): Russell Lane and Paul Davies. Primary headaches are a continuum driven by a common process. Discover Medicine, Oct 2024. URL: https://doi.org/10.1007/s44337-024-00068-w, doi:10.1007/s44337-024-00068-w. This article has 3 citations.
(lane2024primaryheadachesare pages 11-12): Russell Lane and Paul Davies. Primary headaches are a continuum driven by a common process. Discover Medicine, Oct 2024. URL: https://doi.org/10.1007/s44337-024-00068-w, doi:10.1007/s44337-024-00068-w. This article has 3 citations.
(NCT01842763 chunk 1): French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders. Centre Hospitalier Universitaire de Nice. 2013. ClinicalTrials.gov Identifier: NCT01842763
(NCT01842763 chunk 2): French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders. Centre Hospitalier Universitaire de Nice. 2013. ClinicalTrials.gov Identifier: NCT01842763

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	7
Resolved	7
Unresolved (possible confabulation)	0
Unverifiable	0

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Medical Actions

Diagnosis

Prevalence

Differential Diagnoses

Clinical Trials

Source YAML

References & Deep Research

Deep Research

Hemicrania Continua: Disease-Characteristics Research Report

Executive summary

1. Disease information

Definition and classification

Identifiers and synonyms

2. Etiology, risk, and protective factors

Primary and secondary HC

Protective factors

3. Phenotypes

4. Genetic and molecular information

5. Environmental and lifestyle information

6. Mechanism and pathophysiology

Current systems-neuroscience model

Molecular interpretation and limitations

7. Anatomical structures affected

8. Temporal development

9. Epidemiology, inheritance, and population

10. Diagnostics

Clinical diagnosis and indomethacin test

Imaging and other tests

Differential diagnosis

11. Outcome and prognosis

12. Treatment

Indomethacin

Alternatives when indomethacin is contraindicated or intolerable

CGRP-targeted treatment and trials

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Evidence appraisal and curation cautions

Selected authoritative references and exact source statements

Artifacts

Reference Validation